Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT06972719

Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy

Conditions: BRCA1 Mutation, BRCA2 Mutation

Sex: Female

Ages: 19 Years – 50 Years

Healthy volunteers: No

Phase: NA

Enrollment: 50

Sponsor: Duke University

Location: UNC Chapel Hill Health System Chapel Hill North Carolina

Summary

The goal of this study is to develop an educational aid about hormone replacement therapy that physicians can share with patients as part of their pre-surgical counseling for a risk-reducing salpingo-oophorectomy (RRSO).

Eligibility Criteria

Inclusion Criteria: * BRCA1 or BRCA2 germline mutation * scheduled for a risk-reducing salpingo-oophorectomy (RRSO) by Duke Gynecologic Oncologist * premenopausal Exclusion Criteria: * personal history of cancer * postmenopausal * \>50 years old * unable to provide informed consent in English

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06972719). StuddyBuddy aggregates publicly available trial information.